Research
Molecular
The FDA has conditionally approved Resmetirom as the first pharmacological treatment for MASH.
Clinicians should consider Resmetirom as a treatment option for MASH.
StrongSupportsmedium confidence
The Food and Drug Administration's conditional approval of the liver-directed thyroid hormone receptor beta agonist Resmetirom as the first pharmacological treatment for MASH last March 2024.
Why this rating
The claim is based on regulatory approval information.
Source
Safety Choice Drivers of the Coming Treatment Options for Non‐Cirrhotic Metabolic Steatohepatitis
Alessandra Mangia et al. · Liver International · 2025
otherCited 2×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →